Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Two Aquatic Training Models in Physiological Parameters of Elderly Dyslipidemic Women.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02900612
Recruitment Status : Completed
First Posted : September 14, 2016
Last Update Posted : September 14, 2016
Sponsor:
Information provided by (Responsible Party):
Hospital de Clinicas de Porto Alegre

Brief Summary:
This study aims to compare the effects of two water-based training models in physiological parameters of dyslipidemic elderly women. Thus, a randomized controlled clinical trial will be conducted in parallel with the participation of 45 dyslipidemic elderly women.

Condition or disease Intervention/treatment Phase
Dyslipidemias Other: Water aerobics training. Other: Water resistance training. Other: Control Group Not Applicable

Detailed Description:

The women will be randomly divided into three groups: water aerobics training (WA), resistance aquatic training (WR) and the third is the control group (who will perform relaxation sessions under water). The three groups will attend classes during 10 weeks, with two weekly sessions of 45 minutes each. The WA and WR groups will use the same four exercises in their training.

The WA group will be trained using the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.

The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.

Will be measured, before and after the period of 10 weeks of intervention, biochemical, cardiorespiratory, neuromuscular and hemodynamic variables, parameters of quality of life and depressive symptoms in addition to the cardiovascular risk score of the participants of the three groups.

Data will be described by means values and lower and upper limits, with a 95% confidence interval. Comparisons between and within groups were performed using the method of generalized estimates of equations (GEE), with Bonferroni post hoc, adopting a 0.05 significance level.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Two Aquatic Training Models in Physiological Parameters of Elderly Dyslipidemic Women: a Randomized Controlled Clinical Trial.
Study Start Date : December 2015
Actual Primary Completion Date : March 2016
Actual Study Completion Date : May 2016

Arm Intervention/treatment
Experimental: WA (Water Aerobics Training)
Water aerobics training.
Other: Water aerobics training.
The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
Other Name: WA

Experimental: WR (Water Resistance Training)
Resistance aquatic training.
Other: Water resistance training.
The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
Other Name: WR

Active Comparator: CG (Control Group)
Control Group.
Other: Control Group
The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
Other Name: CG




Primary Outcome Measures :
  1. Total Cholesterol (TC) Change [ Time Frame: Change from baseline total cholesterol at 10 weeks ]
    This variable will be measured through blood collection after 12 hours fasting. The analysis will be performed through the enzymatic method using kits Siemens, in automated equipment Advia 1800.


Secondary Outcome Measures :
  1. Triglycerides (TG) Change [ Time Frame: Change from baseline triglycerides at 10 weeks ]
    This variable will be measured through blood collection after 12 hours fasting. The analysis will be performed through the enzymatic method using kits Siemens, in automated equipment Advia 1800.

  2. High Density Lipoprotein (HDL) Change [ Time Frame: Change from baseline HDL at 10 weeks ]
    This variable will be measured through blood collection after 12 hours fasting. The analysis will be performed through the enzymatic method using kits Siemens, in automated equipment Advia 1800.

  3. C-Reactive Protein (CRP) Change [ Time Frame: Change from baseline C-reactive protein at 10 weeks ]
    This variable will be measured through blood collection after 12 hours fasting. The analysis will be performed through the turbidimetric method in Cobas Mira Plus equipment, with the Biotechnical Kit for ultrasensitive C-reactive protein.

  4. Low Density Lipoprotein (LDL) Change [ Time Frame: Change from baseline LDL at 10 weeks ]
    This variable will be estimated by Friedewald equation.

  5. Total Cholesterol/High Density Lipoprotein Ratio (TC/HDL ratio) Change [ Time Frame: Change from baseline TC/HDL at 10 weeks ]
    This variable will be estimated by the simple division of variables.

  6. Peak Oxygen Consumption (VO2peak) Change [ Time Frame: Change from baseline VO2peak at 10 weeks ]
    This outcome will be measure through maximal progressive treadmill test, using the portable gas analyser VO2000 equipment.

  7. Oxygen Consumption at anaerobic threshold (VO2VT2) Change [ Time Frame: Change from baseline VO2VT2 at 10 weeks ]
    This outcome will be measure through maximal progressive treadmill test, using the portable gas analyser VO2000 equipment.

  8. Heart Rate at anaerobic threshold (HRVT2) Change [ Time Frame: Change from baseline HRVT2 at 10 weeks ]
    This outcome will be measure through maximal progressive treadmill test, using a heart rate monitor (POLAR, FT1).

  9. Rest Heart Rate (HRrest) Change [ Time Frame: Change from baseline HRrest at 10 weeks ]
    This outcome will be measure using a heart rate monitor (POLAR, FT1). The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the heart rate.

  10. Lipoprotein Lipase (LPL) Change [ Time Frame: Change from baseline LPL at 10 weeks ]
    This variable will be measured through blood collection after 12 hours fasting. The analysis will be performed using the LPL ELISA kit (Cell Biolabs). The results will be read in a microplate reader (ELISA).

  11. Maximal dynamic muscle strength of knees extensors (MSKE) Change [ Time Frame: Change from baseline MSKE at 10 weeks ]
    This outcome will be measured through the one-repetition maximal test (1RM).

  12. Maximal dynamic muscle strength of knees flexors (MSKF) Change [ Time Frame: Change from baseline MSKF at 10 weeks ]
    This outcome will be measured through the one-repetition maximal test (1RM).

  13. Maximal dynamic muscle strength of horizontal shoulder flexors (MSHSF) Change [ Time Frame: Change from baseline MSHSF at 10 weeks ]
    This outcome will be measured through the one-repetition maximal test (1RM).

  14. Rest Cardiac Output (COrest) Change [ Time Frame: Change from baseline COrest at 10 weeks ]
    This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment). The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the cardiac output.

  15. Rest Stroke Volume (SVrest) Change [ Time Frame: Change from baseline SVrest at 10 weeks ]
    This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment). The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the stroke volume.

  16. Peak Cardiac Output (COpeak) Change [ Time Frame: Change from baseline COpeak at 10 weeks ]
    This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment), during a maximal progressive treadmill test.

  17. Peak Stroke Volume (SVpeak) Change [ Time Frame: Change from baseline SVpeak at 10 weeks ]
    This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment), during a maximal progressive treadmill test.

  18. Rest Arterial Systolic Blood Pressure (SBPrest) Change [ Time Frame: Change from baseline SBPrest at 10 weeks ]
    This outcome will be measured through blood pressure ambulatory monitor (Meditech, ABPM-04). The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the arterial systolic blood pressure.

  19. Rest Arterial Diastolic Blood Pressure (DBPrest) Change [ Time Frame: Change from baseline DBPrest at 10 weeks ]
    This outcome will be measured through blood pressure ambulatory monitor (Meditech, ABPM-04). The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the arterial diastolic blood pressure.

  20. Cardiovascular Risk Score (CRS) Change [ Time Frame: Change from baseline cardiovascular risk score at 10 weeks ]
    The Reynolds Risk Score Instrument will be used to estimate the cardiovascular risk.

  21. Quality of Life Change [ Time Frame: Change from baseline quality of life at 10 weeks ]
    The quality of life will be estimated using the Whoqol-Bref instrument.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • being female, aged between 60 and 75, sedentary (not practicing any kind of regular, supervised physical activity in the last three months), have any type of dyslipidemia.

Exclusion Criteria:

  • women who are smokers, suffering from cardiovascular disease with associated complications and those with orthopedic diseases that prevented the practice of systematic physical exercise, users of hormone therapy drugs and lipid-lowering medications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02900612


Sponsors and Collaborators
Hospital de Clinicas de Porto Alegre
Investigators
Layout table for investigator information
Principal Investigator: Ricardo Stein Hospital de Clinicas de Porto Alegre

Layout table for additonal information
Responsible Party: Hospital de Clinicas de Porto Alegre
ClinicalTrials.gov Identifier: NCT02900612     History of Changes
Other Study ID Numbers: 14-0547
First Posted: September 14, 2016    Key Record Dates
Last Update Posted: September 14, 2016
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Hospital de Clinicas de Porto Alegre:
dyslipidemias,
aging
water aerobics training
resistance aquatic training
lipid profile
Additional relevant MeSH terms:
Layout table for MeSH terms
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases